ATRA - Atara Biotherapeutics, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Income statement
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2019
31/12/2018
31/12/2017
31/12/2016
Total revenue
0
0
0
0
0
Operating expenses
Research development
225,088
216,097
167,457
81,206
56,514
Selling general and administrative
77,399
79,584
69,654
40,326
24,728
Total operating expenses
302,487
295,681
237,111
121,532
81,242
Operating income or loss
-302,487
-295,681
-237,111
-121,532
-81,242
Income before tax
-298,216
-290,964
-230,743
-119,505
-79,039
Income tax expense
-
12
-44
-14
10
Income from continuing operations
-298,228
-290,976
-230,699
-119,491
-79,049
Net income
-298,228
-290,976
-230,699
-119,491
-79,049
Net income available to common shareholders
-298,228
-290,976
-230,699
-119,491
-79,049
Basic EPS
-
-
-5.27
-4.00
-2.75
Diluted EPS
-
-
-5.27
-4.00
-2.75
Basic average shares
-
-
43,811
29,863
28,732
Diluted average shares
-
-
43,811
29,863
28,732
EBITDA
-
-288,611
-233,379
-120,576
-80,859
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more